GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT06082960
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 192
- Registration Number
- NCT06051617
- Locations
- 🇺🇸
SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸University of California, Davis Medical Center, Sacramento, California, United States
Study of GS-0272 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 87
- Registration Number
- NCT06031415
- Locations
- 🇺🇸
1238 E. Arrow Hwy, Upland, California, United States
🇺🇸1600 Republic Parkway, Mesquite, Texas, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 176
- Registration Number
- NCT06029972
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Canada
🇨🇦TDDA Speciality Research, Vaughan, Canada
🇫🇷Centre Hospitalier Universitaire Grenoble, Grenoble Cedex 9, France
Study of Obeldesivir in Children and Adolescents With COVID-19
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT05996744
- Locations
- 🇺🇸
UF Health- Shands Hospital, Gainesville, Florida, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Trinity Clinical Research, LLC, Centreville, Alabama, United States
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 654
- Registration Number
- NCT05840211
- Locations
- 🇰🇷
Samsung Medical Center, Gangnam-Gu, Korea, Republic of
🇲🇽Centro de Atención e Investigación Clínica en Oncología, Yucatán, Mexico
🇵🇱Wojewodzki Szpital Specjalistyczny lm. Stefana Kardynala Wyszynsklego SPZOZ w Lublinie, Lublin, Poland
Study of GS-4528 in Adults With Solid Tumors
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 132
- Registration Number
- NCT05840224
- Locations
- 🇨🇳
Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation, Taoyuan, Taiwan
🇺🇸The University of Washington/FHCC, Seattle, Washington, United States
🇪🇸START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I, Madrid, Spain
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05770895
- Locations
- 🇨🇳
St. Martin De Porres Hospital, Chiayi City, Taiwan
🇨🇳E-DA Hospital, Kaohsiung City, Taiwan
🇨🇳Chia-Yi Christian Hospital, Chiayi City, Taiwan
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT05765344
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
🇺🇸University of Miami, Miami, Florida, United States
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 41
- Registration Number
- NCT05760300
- Locations
- 🇺🇸
Velocity Clinical Research, New Smyrna Beach, Edgewater, Florida, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Floridian Clinical Research, LLC, Miami Lakes, Florida, United States